Abstract
Anemia is a frequent diagnosis in medicine. Anemia can be present as a disease by itself or can be the consequence of another disease. Anemia is particularly common in patients with cancer (Groopman and Itri 1999; Ludwig et al. 2004; Pirker et al. 2005). The incidence and severity of cancer—related anemia depend on cancer type, tumor stage, duration of the cancer, patient age, type as well as intensity of anticancer therapy, and on bone marrow reserve (Groopman and Itri 1999; Ludwig and Strasser 2001; Ludwig et al. 2004; Pirker et al. 2005). Cancer-related anemia can be caused by myelosuppressive chemotherapy and radiotherapy, tumor infiltration of the bone marrow, relative deficiency of erythropoietin, inappropriate response of the bone marrow, functional iron deficiency, nutritional deficiencies, bleeding, hemolysis, cytokines, anemia of chronic disease, and other factors (Cotran et al. 1999; Groopman and Itri 1999). The anemia of chronic disease is the most common type of non-treatment-induced anemia in patients with cancer (DeRienzo and Saleem 1990; Krantz 1994) and is caused by mainly an impaired marrow response to erythropoietin and partly also by a relative inadequacy of erythropoietin production (Dowlati 1997).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cotran RS, Kumar V, Collins T (1999) Red cell and bleeding disorders. In: Cotran RS, Kumar V, Collins T (eds.) Robbins pathologic basis of disease. WB Saunders Company, Philadelphia pp. 601–43
Bohlius J, Wilson J, Seidenfeld J, et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98: 708–14
Caro JJ, Salas M, Ward A, et al (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91: 2214–21
Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 [Suppl 2]: 13–9
Cella D, Zagari MJ, Vandoros C, et al (2003) Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21: 366–73
Curt GA, Breitbart W, Cella D, et al (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5: 353–60
DeRienzo DP, Saleem A (1990) Anemia of chronic disease: a review of pathogenesis. Tex Med 86: 80–3
Dowlati A, R’Zik S, Fillet G, et al (1997) Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. Br J Haematol 97: 297–9
Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 228: 1–14
Groopman JE, Itri LM (1999) Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91: 1616–34
Krantz SB (1994) Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 307: 353–9
Ludwig H, Strasser K (2001) Symptomatology of anemia. Semin Oncol 28 [Suppl 8]: 7–14
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293–306
Pirker R, Wiesenberger K, Minar W (2005) Cancer-related anemia: clinical relevance and treatment strategies. Am J Cancer 4: 233–45
Portenoy RK, Itri LM (1999) Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4: 1–10
Rizzo JD, Lichtin AE, Woolf SH, et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20: 4083–107
Seidenfeld J, Piper M, Flamm C, et al (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93: 1204–14
Stone P, Richards M, A’Hern R, et al (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11: 561–7
Vansteenkiste J, Pirker R, Massuti B, et al (2002) Double-blind, placebocontrolled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94: 1211–20
Vogelzang NJ, Breitbart W, Cella D, et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 [Suppl 2]: 4–12
World Health Organization (1968) Nutritional anemias. Reports of a WHO scientific group. Geneva
Yellen SB, Cella DF, Webster K, et al (1997) Measuring fatigue and other anemiarelated symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13: 63–74
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag/Wien
About this chapter
Cite this chapter
Pirker, R. (2008). Symptoms of anemia. In: Nowrousian, M.R. (eds) Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Springer, Vienna. https://doi.org/10.1007/978-3-211-69459-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-211-69459-6_12
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-25223-9
Online ISBN: 978-3-211-69459-6
eBook Packages: MedicineMedicine (R0)